The changing face of Parkinson's disease-associated psychosis: A cross-sectional study based on the new NINDS-NIMH criteria

Movement Disorders

Volumn 25, Issue 6, 2010, Pages 763-766

  Fénelon, Gilles ^a,b   Soulas, Thierry ^c   Zenasni, Franck ^c   De Langavant, Laurent Cleret ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Delusions; Hallucinations; Parkinson's disease; Psychosis

Indexed keywords

CLOZAPINE; LEVODOPA; PSYCHOTROPIC AGENT;

AGED; ARTICLE; COMPUTER PROGRAM; CROSS-SECTIONAL STUDY; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; STRUCTURED QUESTIONNAIRE; SYMPTOM; VISUAL HALLUCINATION;

EID: 77951833322     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22839     Document Type: Article

References (15)

1. Fénelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of the pathophysiologic mechanisms. CNS Spectrums 2008;13(suppl 4):18-25. (Pubitemid 351532445)
2. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2007;22:1061-1068. (Pubitemid 47067214)
3. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
4. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006;28:1-12. (Pubitemid 43254985)
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th ed (DSM IV). Washington, DC: American Psychiatric Association; 1994.
6. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
7. Chou K, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28:215-219. (Pubitemid 41579618)
8. Goetz CG, Wuu J, Curgian L, leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 2006;21:267-270.
9. Papapetropoulos S, Katzen H, Schrag A, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol 2008;8:21.
10. Fernandez HH, Aarsland D, Fénelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:484-500.
11. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130-140.
12. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005;28:737-757. (Pubitemid 43372762)
13. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions and REM behavior disorder in Parkinson's disease. Mov Disord 2005;20:1439-1448. (Pubitemid 43072652)
14. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 2008;79:652-655.
15. Poewe W. When a Parkinson's disease patient starts to hallucinate. Pract Neurol 2008;8:238-241.